RxDoctor Payments Data

Aliza Alter, MD

Neurology with Special Qualifications in Child Neurology · Livingston, NJNPI 1457794257

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by UCB Biosciences Inc. at 35.9% of the total. 2025 is the largest year on record at $4,144, more than ten times the $15 reported in 2019. Among neurology with special qualifications in child neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,941in general payments, 2019–2025

Across 221 payments — averaging $40.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB Biosciences Inc.$3K
  • H. Lundbeck A S$2K
  • Supernus Pharmaceuticals, Inc.$727
  • Neuropace, Inc.$320
  • AbbVie$310
  • SK Life Science, Inc.$310
  • plus $2K from 37 others
$14,389in research payments, 2019–2025

Across 19 payments — averaging $757.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Immedica Pharma US, Inc.$14K

What the payments were for

  • Speaking & faculty fees$3,20736%
  • Travel & lodging$1,61418%
  • Food & beverage$4,12046%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,941 in reported general payments places this provider in the 95th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.

See all neurology with special qualifications in child neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$68,357
Medicare patients
295
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lorazepam11$30

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Livingston

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →